|
MechanismTNF-α inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date31 Dec 2002 |
|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date02 May 1975 |
AMLM22/D2-The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 2 is investigating the safety and efficacy of Venetoclax as a maintenance therapy alone or in combination with low dose cytarabine (LDAC).
A two stage, epidemiological, cross-sectional survey study of the Australian population, to determine the prevalence and severity of Hidradenitis Suppurativa (HS).
Hurley staging versus self administered questionnaire to determine the severity of Hydradentitis Suppurativa
100 Clinical Results associated with AbbVie (Pty) Ltd. (South Africa)
0 Patents (Medical) associated with AbbVie (Pty) Ltd. (South Africa)
100 Deals associated with AbbVie (Pty) Ltd. (South Africa)
100 Translational Medicine associated with AbbVie (Pty) Ltd. (South Africa)